BioXcel down 64% - no, it’s not the data problem, it’s the drug doesn’t work very well

BioXcel (NASDAQ: BTAI) stock dropped like a stone yesterday, 64% down. This was on the announcement of results from the Tranquility II trials into BXCL501. There was a data issue, the sort of thing that the FDA frowns upon and so on. But the real problem here is that the drug just doesn't seem to work very well. Sure, it has an effect. But then it takes a long time to do so, doesn't have all that much of an effect and there are other, cheaper, faster, ways of gaining that effect. Which is not, you know, a ringing endorsement of the treatment.

BioXcel does have a problem here: “For example, the FDA cited the principal investigator's delay in informing the sponsor's medical monitor or pharmacovigilance safety vendor of a serious adverse event (“SAE”) for one of the subjects, which report was made to the Company's vendor outside of the 24 hour time period prescribed by the clinical trial protocol. The principal investigator for this clinical site responded to the FDA observations within the time period requested. The FDA inspection remains open, however, as the FDA has not issued an Establishment Inspection Report.” Well, that can sound like just not crossing ts and dotting is. But the FDA takes such things seriously because one error might be indicative of others in the testing program. Yes, even though this was an adverse event with the placebo, there are still going to be inspectors crawling all over this.

BioXcel stock price from NASDAQ

But the real problem is that the drug, while it has passed the test, doesn't seem to be very good. Note that this isn't about treating Alzheimer's - it's about treating the agitation that can often be associated with it. And, well, there are many ways of treating agitation. Like, a sedative. And that leads to this problem:  “is this effect really meaningful. The scale is 5-35, so giving a placebo gets you down 5 and the drug gets you down just 2 more... which you get if you wait anyways? AND you have to wait a whole 2 hours for that small effect, statistically. Plus, the drug only seems to work as a sedative anyways.. with a half life of 2.5 h.” Sure, that's just no name commentary on a stock picking site. But it does get to the nub of the matter. 

#Even if we assume that the data problem will get resolved - it probably will - and also the drug moves through to approval - entirely possible. We've still got the problem of how many doctors are going to prescribe it when there are other, better, faster, solutions available? 

Which is the real problem here at BioXcel. The drug just turns out not to be very good.